Patents by Inventor Jane Ung

Jane Ung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230322806
    Abstract: The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer.
    Type: Application
    Filed: March 17, 2023
    Publication date: October 12, 2023
    Inventors: Evan W. Rogers, Jane Ung, Vivian Nguyen, Dayong Zhai, Wei Deng, Jingrong J. Cui
  • Patent number: 11634433
    Abstract: The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer.
    Type: Grant
    Filed: December 2, 2020
    Date of Patent: April 25, 2023
    Assignee: TURNING POINT THERAPEUTICS, INC.
    Inventors: Evan W. Rogers, Jane Ung, Vivian Nguyen, Dayong Zhai, Wei Deng, Jingrong J. Cui
  • Publication number: 20220324879
    Abstract: The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.
    Type: Application
    Filed: February 22, 2022
    Publication date: October 13, 2022
    Inventors: Jingrong Jean Cui, Evan W. Rogers, Jane Ung, Jeffrey Whitten, Dayong Zhai, Wei Deng, Xin Zhang, Zhongdong Huang, Jing Liu, Han Zhang
  • Publication number: 20220306652
    Abstract: The present disclosure relates to certain macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat disease, such as cancer.
    Type: Application
    Filed: February 14, 2022
    Publication date: September 29, 2022
    Inventors: Evan W. Rogers, Jingrong J. Cui, Dayong Zhai, Han Zhang, Jane Ung, Wei Deng, Jeffrey Whitten
  • Patent number: 11286264
    Abstract: The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: March 29, 2022
    Assignee: TURNING POINT THERAPEUTICS, INC.
    Inventors: Jingrong Jean Cui, Evan W. Rogers, Jane Ung, Jeffrey Whitten, Dayong Zhai, Wei Deng, Xin Zhang, Zhongdong Huang, Jing Liu, Han Zhang
  • Patent number: 11286265
    Abstract: The present disclosure relates to certain macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat disease, such as cancer.
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: March 29, 2022
    Assignee: TURNING POINT THERAPEUTICS, INC.
    Inventors: Evan W. Rogers, Jingrong J. Cui, Dayong Zhai, Han Zhang, Jane Ung, Wei Deng, Jeffrey Whitten
  • Patent number: 11155563
    Abstract: The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: October 26, 2021
    Assignee: Turning Point Therapeutics, Inc.
    Inventors: Jingrong Jean Cui, Evan W. Rogers, Jane Ung, Jeffrey Whitten, Dayong Zhai, Wei Deng, Xin Zhang, Zhongdong Huang, Jing Liu, Han Zhang
  • Patent number: 11142533
    Abstract: The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer.
    Type: Grant
    Filed: March 26, 2021
    Date of Patent: October 12, 2021
    Assignee: Turning Point Therapeutics, Inc.
    Inventors: Evan W. Rogers, Jane Ung, Vivian Nguyen, Dayong Zhai, Wei Deng, Jingrong J. Cui
  • Publication number: 20210246145
    Abstract: The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer.
    Type: Application
    Filed: March 26, 2021
    Publication date: August 12, 2021
    Inventors: Evan W. Rogers, Jane Ung, Vivian Nguyen, Dayong Zhai, Wei Deng, Jingrong J. Cui
  • Publication number: 20210214373
    Abstract: The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.
    Type: Application
    Filed: March 25, 2021
    Publication date: July 15, 2021
    Inventors: Jingrong Jean Cui, Evan W. Rogers, Jane Ung, Jeffrey Whitten, Dayong Zhai, Wei Deng, Xin Zhang, Zhongdong Huang, Jing Liu, Han Zhang
  • Patent number: 11028052
    Abstract: The present invention includes compounds useful as modulators of TRPM8, such as compounds of Formulae (Ia), (Ib) and (Ic), and the subgenus and species thereof; personal products containing those compounds; and the use of those compounds and the personal products, particularly the use of increasing or inducing chemesthetic sensations, such as cooling or cold sensations.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: June 8, 2021
    Assignee: Firmenich Incorporated
    Inventors: Lyudmyla Chumakova, Andrew Patron, Chad Priest, Donald Karanewsky, Rachel Kimmich, Brant Clayton Boren, Jeffrey Robert Hammaker, Volodymyr Chumakov, Wen Zhao, Alain Noncovich, Jane Ung
  • Publication number: 20210163499
    Abstract: The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer.
    Type: Application
    Filed: December 2, 2020
    Publication date: June 3, 2021
    Inventors: Evan W. Rogers, Jane Ung, Vivian Nguyen, Dayong Zhai, Wei Deng, Jingrong J. Cui
  • Patent number: 11008337
    Abstract: The present disclosure relates to certain chiral diaryl macrocyclic derivatives, of the formula I: pharmaceutical compositions containing them, and methods of using them to treat cancer, pain, neurological diseases, autoimmune diseases, and inflammation.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: May 18, 2021
    Assignee: Turning Point Therapeutics, Inc.
    Inventors: Jingrong J. Cui, Yishan Li, Evan W. Rogers, Dayong Zhai, Wei Deng, Jane Ung
  • Publication number: 20210087206
    Abstract: The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer, pain, neurological diseases, autoimmune diseases, and inflammation.
    Type: Application
    Filed: December 18, 2018
    Publication date: March 25, 2021
    Inventors: Evan W. ROGERS, Jane UNG, Han ZHANG, Jeffrey WHITTEN, Dayong ZHAI, Wei DENG, Jingrong Jean CUI
  • Patent number: 10953007
    Abstract: The present invention includes compounds useful as modulators of TRPM8, such as compounds of Formula (I) and the subgenus and species thereof; personal products containing those compounds; and the use of those compounds and the personal products, particularly the use of increasing or inducing chemesthetic sensations, such as cooling or cold sensations.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: March 23, 2021
    Assignee: Firmenich Incorporated
    Inventors: Chad Priest, Alain Noncovich, Andrew Patron, Jane Ung
  • Publication number: 20200392160
    Abstract: The present disclosure relates to certain macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat disease, such as cancer.
    Type: Application
    Filed: May 5, 2020
    Publication date: December 17, 2020
    Inventors: Evan W. Rogers, Jingrong J. Cui, Dayong Zhai, Han Zhang, Jane Ung, Wei Deng, Jeffrey Whitten
  • Patent number: 10745416
    Abstract: The present disclosure relates to certain macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat disease, such as cancer.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: August 18, 2020
    Assignee: Turning Point Therapeutics, Inc.
    Inventors: Evan W. Rogers, Jingrong J. Cui, Dayong Zhai, Han Zhang, Jane Ung, Wei Deng, Jeffrey Whitten
  • Patent number: 10689400
    Abstract: The present disclosure relates to certain macrocyclic kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same to treat disease.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: June 23, 2020
    Assignee: Turning Point Therapeutics, Inc.
    Inventors: Jingrong Jean Cui, Yishan Li, Evan W. Rogers, Dayong Zhai, Jane Ung
  • Publication number: 20200190110
    Abstract: The present disclosure relates to certain macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat disease, such as cancer.
    Type: Application
    Filed: January 30, 2020
    Publication date: June 18, 2020
    Applicant: Turning Point Therapeutics, Inc.
    Inventors: Evan W. Rogers, Jingrong J. Cui, Dayong Zhai, Han Zhang, Jane Ung, Wei Deng, Jeffrey Whitten
  • Publication number: 20200157119
    Abstract: The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.
    Type: Application
    Filed: July 26, 2018
    Publication date: May 21, 2020
    Inventors: Jingrong Jean CUI, Evan W. ROGERS, Jane UNG, Jeffrey Whitten, Dayong Zhai, Wei DENG, Xin ZHANG, Zhongdong HUANG, Jing LIU, Han ZHANG